| Insurer pricing and consumer welfare: Evidence from medigap A Starc The RAND Journal of Economics 45 (1), 198-220, 2014 | 170 | 2014 |
| Who benefits when the government pays more? Pass-through in the Medicare Advantage program M Duggan, A Starc, B Vabson Journal of Public Economics 141, 50-67, 2016 | 153 | 2016 |
| Pricing regulation and imperfect competition on the massachusetts health insurance exchange KMM Ericson, A Starc Review of Economics and Statistics 97 (3), 667-682, 2015 | 137 | 2015 |
| How product standardization affects choice: Evidence from the Massachusetts Health Insurance Exchange KMM Ericson, A Starc Journal of Health Economics 50, 71-85, 2016 | 117 | 2016 |
| Ask your doctor? Direct-to-consumer advertising of pharmaceuticals M Sinkinson, A Starc The Review of Economic Studies 86 (2), 836-881, 2019 | 113 | 2019 |
| Heuristics and heterogeneity in health insurance exchanges: Evidence from the Massachusetts connector KM Ericson, A Starc American Economic Review 102 (3), 493-497, 2012 | 93 | 2012 |
| Externalities and benefit design in health insurance A Starc, RJ Town The Review of Economic Studies 87 (6), 2827-2858, 2020 | 71* | 2020 |
| Mortality effects and choice across private health insurance plans J Abaluck, M Caceres Bravo, P Hull, A Starc The quarterly journal of economics 136 (3), 1557-1610, 2021 | 68 | 2021 |
| Measuring consumer valuation of limited provider networks KM Ericson, A Starc American Economic Review 105 (5), 115-119, 2015 | 66 | 2015 |
| A dose of managed care: Controlling drug spending in medicaid D Dranove, C Ody, A Starc American Economic Journal: Applied Economics 13 (1), 170-197, 2021 | 34* | 2021 |
| Inferring risk perceptions and preferences using choice from insurance menus: theory and evidence KM Ericson, P Kircher, J Spinnewijn, A Starc National Bureau of Economic Research, 2015 | 32* | 2015 |
| Preferred pharmacy networks and drug costs A Starc, A Swanson American Economic Journal: Economic Policy 13 (3), 406-446, 2021 | 30 | 2021 |
| How important is price variation between health insurers? SV Craig, KM Ericson, A Starc Journal of Health Economics 77, 102423, 2021 | 30 | 2021 |
| Endogenous quality investments in the US hospital market C Garthwaite, C Ody, A Starc Journal of Health Economics 84, 102636, 2022 | 23 | 2022 |
| Designing and regulating health insurance exchanges: lessons from Massachusetts KMM Ericson, A Starc INQUIRY: The Journal of Health Care Organization, Provision, and Financing …, 2012 | 16 | 2012 |
| Does entry remedy collusion? Evidence from the generic prescription drug cartel A Starc, TG Wollmann National Bureau of Economic Research, 2022 | 10 | 2022 |
| Getting the price right? The impact of competitive bidding in the Medicare program H Ding, M Duggan, A Starc Review of Economics and Statistics, 1-45, 2022 | 5 | 2022 |
| Multidimensional Screening and Menu Design in Health Insurance Markets H Chade, VR Marone, A Starc, J Swinkels National Bureau of Economic Research, 2022 | 2 | 2022 |
| Why Drug Pricing Reform Is Complicated: A Primer and Policy Guide to Pharmaceutical Prices in the US C Garthwaite, A Starc | | 2023 |
| Manufacturer Spending on Direct-to-Consumer Advertising for Pharmaceutical Products A Starc JAMA 329 (5), 371-373, 2023 | | 2023 |
Keith M Marzilli EricsonAssociate Professor of Markets, Public Policy, and Law at Boston UniversityVerified email at bu.edu
